SENATE AMENDMENT

    Bill No. CS for SB 168

    Amendment No.    

                            CHAMBER ACTION
              Senate                               House
                                   .
                                   .
 1                                 .
                                   .
 2                                 .
                                   .
 3                                 .
                                   .
 4                                                                

 5

 6

 7

 8

 9

10                                                                

11  Senators Latvala and Silver moved the following amendment:

12

13         Senate Amendment (with title amendment) 

14         On page 2, between lines 20 and 21,

15

16  insert:

17         Section 2.  The Board of Medicine and the Board of

18  Pharmacy shall jointly submit a report to the Legislature by

19  January 1, 2001, which recommends whether the formulary for

20  generic and brand-name drugs required by section 465.025(6),

21  Florida Statutes, should be retained. If the report recommends

22  retention of the formulary established under section

23  465.025(6), Florida Statutes, the report must specify how

24  further restrictions on generic-drug substitution will be

25  based solely on scientific evidence of drug equivalency and

26  what standards should be used in making such determinations.

27  The report must also estimate the costs of making

28  drug-equivalency determinations in this state.

29         Section 3.  Effective July 1, 2000, the Board of

30  Pharmacy and the Board of Medicine shall remove from the

31  formulary established under section 465.025(6), Florida

                                  1
    4:07 PM   04/04/00                              s0168c1c-19j02




                                                  SENATE AMENDMENT

    Bill No. CS for SB 168

    Amendment No.    





 1  Statutes, all drugs that have been determined therapeutically

 2  equivalent or AB-rated in "Approved Drug Products with

 3  Therapeutic Equivalence Evaluations" (Orange Book) published

 4  by the federal Food and Drug Administration.

 5

 6  (Redesignate subsequent sections.)

 7

 8

 9  ================ T I T L E   A M E N D M E N T ===============

10  And the title is amended as follows:

11         On page 1, line 5, after the semicolon,

12

13  insert:

14         requiring that the Board of Medicine and the

15         Board of Pharmacy recommend to the Legislature

16         whether the drug formulary required under s.

17         465.025(6), F.S., should be retained; requiring

18         that certain drugs be removed from the

19         formulary by a specified date;

20

21

22

23

24

25

26

27

28

29

30

31

                                  2
    4:07 PM   04/04/00                              s0168c1c-19j02